Beta Drugs Limited — Others, 15-05-2025: Monitoring Agency Report

Beta Drugs Limited has shared a Monitoring Agency Report on the use of ₹117.02 Cr raised through preferential equity shares and CCDs. About ₹12.55 Cr has been spent on subsidiary facility upgrades, R&D, and advisory services, while ₹104.46 Cr is parked in fixed deposits earning 6.5-7.7% interest. The funds support expansion, manufacturing capex, and general corporate purposes. There are no delays or deviations in deployment, reflecting steady progress on growth initiatives and prudent cash management for shareholders.